Zymeworks Inc. Common Stock (ZYME) — Capital Reinvestment Ratio
Latest as of June 2025:
0.07x
Zymeworks Inc. Common Stock (ZYME) has a Capital Reinvestment Ratio of 0.07x as of June 2025, meaning it reinvests 0% of its operating cash flow ($12.07 Million) in capital expenditures ($884.00K). See ZYME free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.07x
Capex / Operating Cash Flow
Operating Cash Flow
$12.07 Million
USD
Capital Expenditures
$884.00K
USD
Data as of
Jun 2025
Most recent filing
Zymeworks Inc. Common Stock Capital Reinvestment Ratio (2017–2022)
This chart tracks Zymeworks Inc. Common Stock's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for Zymeworks Inc. Common Stock (2017–2022)
Year-by-year Capital Reinvestment Ratio for Zymeworks Inc. Common Stock from 2017 to 2022. For live market cap and broader valuation context, see market value of Zymeworks Inc. Common Stock.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.09x | $144.11 Million | $13.12 Million | ▼ -35.6% |
| 2018 | 0.14x | $24.18 Million | $3.42 Million | ▼ -99.0% |
| 2017 | 14.25x | $219.00K | $3.12 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow